MedDataX Logo

A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis

NCT ID: NCT01008995

Last Updated: 2013-11-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

322 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2011-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, 220 patients will be divided into two groups randomly (by chance), like flipping a coin. Each group will receive a different treatment. The results for each group are compared to each other. There are 2 treatment groups in this study, Group 1 and Group 2. Group 1 will receive placebo at Weeks 0 and 4, ustekinumab 45 mg at Weeks 12 and 16. Group 2 will receive ustekinumab 45 mg at Weeks 0, 4, and 16 and placebo at Week 12. All patients in the study will eventually receive ustekinumab after Week 12. The patients will be in the study for about 36 weeks, with study visit approximately 10 times. Effectiveness evaluations will be conducted throughout the study and include the Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA) and Dermatology Life Quality Index (DLQI). Safety assessments will also be performed throughout the study and include obtaining and evaluating laboratory tests, vital signs (e.g., blood pressure) and the occurrence and severity of adverse events. GROUP 1: Placebo at Weeks 0 and 4, ustekinumab 45 mg at Weeks 12 and 16. GROUP 2: Ustekinumab 45 mg at Weeks 0, 4, and 16. Placebo at Week 12

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

psoriasis asian patients Chinese ustekinumab CNTO 1275 Stelara

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

001

placebo Subcutaneous injection at Week 0 and 4,ustekinumab 45 mg subcutaneous injection at Week 12 and 16

Group Type EXPERIMENTAL

placebo

Intervention Type DRUG

Subcutaneous injection at Week 0 and 4

ustekinumab

Intervention Type DRUG

45 mg subcutaneous injection at Week 12 and 16

002

placebo Subcutaneous injection at Week 12,ustekinumab 45 mg subcutaneous injection at Week 0 4 and 16

Group Type EXPERIMENTAL

placebo

Intervention Type DRUG

Subcutaneous injection at Week 12

ustekinumab

Intervention Type DRUG

45 mg subcutaneous injection at Week 0, 4 and 16

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

placebo

Subcutaneous injection at Week 0 and 4

Intervention Type DRUG

ustekinumab

45 mg subcutaneous injection at Week 12 and 16

Intervention Type DRUG

placebo

Subcutaneous injection at Week 12

Intervention Type DRUG

ustekinumab

45 mg subcutaneous injection at Week 0, 4 and 16

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be of Chinese ancestry
* Have had a diagnosis of plaque-type psoriasis at least 6 months prior to study start
* Have plaque-type psoriasis covering at least 10% of total BSA at screening and at the time of study start
* Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater at study start
* Must be candidates for phototherapy or systemic treatment of psoriasis (either naive or history of previous treatment)

Exclusion Criteria

* Currently have nonplaque forms of psoriasis
* Have current drug-induced psoriasis
* Have used any investigational drug within the previous 4 weeks
* Have used any biologic within the previous 3 months
* Be known to be infected with human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), or syphilis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centocor, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Centocor, Inc. Clinical Trial

Role: STUDY_DIRECTOR

Centocor, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Beijing, , China

Site Status

Chongqing, , China

Site Status

Dalian, , China

Site Status

Guangzhou, , China

Site Status

Hangzhou, , China

Site Status

Nanjing, , China

Site Status

Shanghai, , China

Site Status

Shenyang, , China

Site Status

Xi'an, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C0743T23

Identifier Type: OTHER

Identifier Source: secondary_id

CR016318

Identifier Type: OTHER

Identifier Source: secondary_id

CR016318

Identifier Type: -

Identifier Source: org_study_id